我要投票 MicroPort在医疗器械行业中的票数:128
· 外 推 电 报 ·
2025-02-23 18:28:43 星期日

【MicroPort是哪个国家的品牌?】

MicroPort是什么牌子?「MicroPort」是上海微创医疗器械(集团)有限公司旗下著名品牌。该品牌发源于上海市,由创始人常董在1998年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力MicroPort品牌出海!通过在本页面挂载MicroPort品牌的产品链接和联系邮箱,可以提高MicroPort产品曝光!跨境电商爆单神器,目前只要100元/年哦~

始于1998年,集医疗器械开发、制造及营销于一体,专注于心血管介入产品/骨科医疗器械等研制的集团公司,以药物支架著称


微创®起源于1998年成立的上海微创医疗器械(集团)有限公司,是一家中国出色的创新型医疗器械集团,总部位于中国上海张江科学城(上海市浦东新区张东路1601号) ,在中国上海、苏州、嘉兴、东莞,美国孟菲斯,法国巴黎近郊,意大利米兰近郊和多米尼加共和国等地均建有主要生产(研发)基地,形成了全球化的研发、生产、营销和服务网络。公司现有员工约5,000名,来自于30多个国家,其中过半数为中国员工。微创®专注于通过持续创新,为医生提供能挽救并重塑患者生命或改善其生活质量的真善美惠医疗解决方案。

微创®已上市产品约300个,覆盖心血管介入及结构性心脏病医疗、心脏节律管理及电生理医疗、骨科植入与修复、大动脉及外周血管介入、神经介入及脑科学、糖尿病及内分泌管理、泌尿及妇女健康、外科手术、医疗机器人与人工智能等十大业务集群。微创®的产品已进入全球逾8,000家医院,覆盖亚太、欧洲和美洲等主要地区。在全球范围内,平均每12秒就有一个微创®的产品被用于救治患者生命或改善其生活品质或用于帮助其催生新的生命。2014年推出的药物靶向洗脱支架系统更是令微创®在冠脉支架领域完成了从追随者和并跑者到全球带领者的跨越。

微创®人的创新动力源于一个属于患者和医生的品牌观,一切经营活动的理念和动机皆源自于患者,为了患者和用之于患者;一切创新的想法皆取之于医生,为了医生,并归之于医生。 “日月不以毫末而不照,雨露不以草草而不滋”,微创®人坚定地信仰人人都有生而平等的医疗权、健康权和追求活得更久的权利,并希冀与社会各界通力合作,为人人享有这种权利而积极创造各种各样的变革性医疗手段。微创®的远景(“以人为本,在以微创伤为代表的高科技医学领域建设一个属于患者的全球化医疗集团”)和使命(“持续创新,为医生提供能挽救并重塑患者生命或改善其生活质量的真善美惠医疗解决方案”)的核心就如同呼吸的空气、太阳的光芒和清晨的雨露一样,让代表全球高科技水平的医疗技术以公平、平等的方式,将健康和长寿带给世界上的每一个角落,每一个社区,每一个家庭和每一位患者。

秉承“致广致大致远致良知,尽精尽微尽心尽力”的管理理念,微创®在强调以人为本的同时,将对细节的追求和创新的坚持深深融入到企业基因之中。“患者和医生是并肩作战的战友,微创®是患者和医生的后勤保障,疾病是我们共同的敌人”,“为患者服务”和“为‘为患者服务的医生’服务”是微创®人共同的信仰。微创®人专注于与患者和医生结成命运共同体,缓解甚至消除各种慢性疾病对生命安全的严重威胁,并在把人类平均健康寿命提升至100岁、120岁甚至150岁的过程中,发挥越来越重要、甚至不可或缺的作用,为满足人类对“健康长寿”永无止境的美好追求做出重要贡献。


英文翻译:Started in 1998, it is a group company integrating the development, manufacturing and marketing of medical devices, focusing on the research and development of cardiovascular intervention products / orthopedic medical devices, etc. it is famous for drug stents and minimally invasive medical devices (Group) Co., Ltd., which was founded in 1998. It is an outstanding innovative medical device group in China, headquartered in Zhangjiang Science City, Shanghai, China No. 1601, Zhangdong Road, Pudong New Area, Shanghai, Suzhou, Jiaxing, Dongguan, Memphis, France, Paris, Milan, Italy, Dominican Republic and other places have established major production (R & D) bases, forming a global R & D, production, marketing and service network. The company has about 5000 employees, from more than 30 countries, of which more than half are Chinese employees. Minimally invasive ® focuses on providing doctors with true, good and beautiful medical solutions that can save and reshape patients' lives or improve their quality of life through continuous innovation. Minimally invasive ® has about 300 products on the market, covering ten business clusters, including cardiovascular intervention and structural heart disease medicine, cardiac rhythm management and electrophysiological medicine, orthopedic implantation and repair, large artery and peripheral vascular intervention, neural intervention and brain science, diabetes and endocrine management, urinary and women's health, surgical operation, medical robot and artificial intelligence. Minimally invasive products have entered more than 8000 hospitals around the world, covering major regions such as Asia Pacific, Europe and the Americas. Globally, on average, every 12 seconds, a minimally invasive ® product is used to treat patients' lives or improve their quality of life or to help them generate new lives. The drug-targeted eluting stent system launched in 2014 makes minimally invasive ® complete the leap from follower and parallel runner to global leader in the field of coronary stent. Minimally invasive ® people's innovation power comes from a brand concept belonging to patients and doctors. The concept and motivation of all business activities come from patients, for patients and for patients; all innovative ideas are taken from doctors, for doctors, and for doctors. "The sun and the moon don't shine, the rain and the dew don't nourish with grass and grass". Micro invasive people firmly believe that everyone has the right to health care, the right to health and the right to live longer, and hope to work together with all sectors of society to actively create a variety of transformative medical means for everyone to enjoy this right. Minimally invasive's vision ("people-oriented, building a global medical group for patients in the field of high-tech medicine represented by micro trauma") and mission ("continuous innovation, providing doctors with true, good and beautiful medical solutions that can save and reshape patients' lives or improve their quality of life") are like breathing air, sun's light and morning dew In the same way, let the medical technology representing the global high-tech level bring health and longevity to every corner, every community, every family and every patient in a fair and equal way. Adhering to the management concept of "broad to the general, far to the conscience, meticulous to the utmost", micro invasive ® emphasizes people-oriented and deeply integrates the pursuit of details and innovation into the corporate gene. "Patients and doctors are comrades in arms, minimally invasive ® is the logistical support for patients and doctors, disease is our common enemy," serve patients "and" serve doctors for patients "are the common beliefs of minimally invasive ® people. Micro invasive people focus on forming a community of common destiny with patients and doctors to alleviate or even eliminate the serious threat of various chronic diseases to life safety, and play an increasingly important, even indispensable role in raising the average healthy life span of human beings to 100, 120 or even 150 years old, so as to make an important contribution to meet the endless pursuit of "healthy and long life" Offer.

本文链接: https://www.waitui.com/brand/21726326e.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

天岳先进:2024年净利润1.8亿元 同比扭亏为盈

36氪获悉,天岳先进发布业绩快报,公司2024年实现营业收入17.68亿元,同比增长41.37%;实现归属于母公司所有者的净利润1.80亿元,同比扭亏为盈。主要原因是公司大尺寸、导电型产品产能产量持续提升,销售量增加,同时产品毛利率上升。

29分钟前

小米集团卢伟冰:小米15 Ultra会是越级式的一代产品

36氪获悉,小米集团合伙人兼总裁、手机部总裁、小米品牌总经理卢伟冰发文称,小米手机未来5年高端化的目标之一,就是要在6000元+价格段实现规模化的突破,“Ultra是6K+突破的关键产品,而小米15 Ultra会是越级式的一代产品”。

29分钟前

恒瑞医药:羟乙磺酸达尔西利片联合内分泌治疗乳腺癌III期临床试验达主要终点

36氪获悉,恒瑞医药公告称,公司自主研发的羟乙磺酸达尔西利片在激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性女性乳腺癌辅助治疗的III期临床试验中,首次期中分析主要终点达到统计学显著性。研究结果显示,达尔西利联合内分泌治疗可显著降低患者复发风险,提高患者无侵袭性疾病生存期(IDFS)。公司已向国家药品监督管理局药品审评中心递交上市前沟通交流申请。该药品是公司自主研发的化学药品1类新药,是一种口服、高效、选择性的小分子CDK4/6抑制剂。

29分钟前

深圳:近期将发布人形机器人专项政策 在全市科技重大专项中安排人工智能和机器人专项

深圳市政府新闻办2月23日召开“打造最好科技创新生态和人才发展环境”主题新闻发布会。市人工智能产业办主任林毅在会上表示,深圳在人工智能和机器人领域基础雄厚、未来可期。下一步,我们将在政策、场景、创新、机器人四个方面持续发力。此外,近期我们还将发布人形机器人专项政策,通过“揭榜挂帅”等方式,对开放应用场景、突破关键技术、构建专用数据集、提升规模化制造和应用能力等予以精准支持。同时,还将在全市科技重大专项中安排人工智能和机器人专项,鼓励产、学、研、用组成创新联合体进行协同攻关。(财联社)

29分钟前

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

29分钟前

本页详细列出关于海氏海诺的品牌信息,含品牌所属公司介绍,海氏海诺所处行业的品牌地位及优势。
咨询